Back to News
Market Impact: 0.35
Vaxcyte Commences Proposed $500 Mln Equity & $500 Mln Notes Offering To Fund VAX-31 Program
Source: Nasdaq
Healthcare & BiotechCredit & Bond MarketsCompany Fundamentals
Vaxcyte commenced two separate underwritten offerings: $500 million of common stock and pre-funded warrants, and $500 million aggregate principal amount of convertible senior notes due 2032. The announcement describes up to $1 billion in financing, including equity-linked securities; pricing and proceeds details were not provided.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly negative
Sentiment Score
-0.15
Ticker Sentiment
PCVX-0.30
More News
- Stock Movers: Constellation Energy, Moderna, Marvell (Podcast)
- Stock Movers: Constellation Brands, Seagate, Biotech (Podcast)
- Vaxcyte Announces Pricing of Concurrent Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes
- Why Dangote’s Nigeria Refinery IPO Is Such a Big Deal for Africa
- A 32% beat, a +6% jump: the IT solutions name our models picked in July
- Nvidia Is on the Verge of a $6 Trillion Market Value